AU2020414737A1 - Methods and systems for molecular disease assessment via analysis of circulating tumor DNA - Google Patents
Methods and systems for molecular disease assessment via analysis of circulating tumor DNA Download PDFInfo
- Publication number
- AU2020414737A1 AU2020414737A1 AU2020414737A AU2020414737A AU2020414737A1 AU 2020414737 A1 AU2020414737 A1 AU 2020414737A1 AU 2020414737 A AU2020414737 A AU 2020414737A AU 2020414737 A AU2020414737 A AU 2020414737A AU 2020414737 A1 AU2020414737 A1 AU 2020414737A1
- Authority
- AU
- Australia
- Prior art keywords
- subject
- tumor
- sequencing
- cancer
- methylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953368P | 2019-12-24 | 2019-12-24 | |
| US62/953,368 | 2019-12-24 | ||
| US202062993564P | 2020-03-23 | 2020-03-23 | |
| US62/993,564 | 2020-03-23 | ||
| PCT/US2020/066976 WO2021133993A2 (en) | 2019-12-24 | 2020-12-23 | Methods and systems for molecular disease assessment via analysis of circulating tumor dna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020414737A1 true AU2020414737A1 (en) | 2022-07-14 |
Family
ID=76575344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020414737A Abandoned AU2020414737A1 (en) | 2019-12-24 | 2020-12-23 | Methods and systems for molecular disease assessment via analysis of circulating tumor DNA |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230135171A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4081665A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023508947A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115087749A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020414737A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3165763A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI893039B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021133993A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12592321B2 (en) | 2020-06-19 | 2026-03-31 | University Health Network | Cancer detection and classification using methylome analysis |
| CA3226747A1 (en) * | 2021-07-27 | 2023-02-02 | Chunxiao Song | Compositions and methods related to tet-assisted pyridine borane sequencing for cell-free dna |
| EP4405507A4 (en) * | 2021-09-20 | 2025-11-05 | Droplet Biosciences Inc | METHODS FOR DISEASE ASSESSMENT USING A DRAINAGE FLUID |
| EP4433607A4 (en) * | 2021-11-19 | 2025-10-15 | Found Medicine Inc | FRAGMENT CONSENSUS METHODS FOR ULTRASENSITIVE DETECTION OF ABERRANT METHYLATION |
| CN114703284A (zh) * | 2022-04-15 | 2022-07-05 | 北京莱盟君泰国际医疗技术开发有限公司 | 一种血液游离dna甲基化定量检测方法及其应用 |
| KR102789317B1 (ko) * | 2023-10-06 | 2025-04-02 | (주)지놈포미 | 고심도 세포 유리 핵산 시퀀싱 기반의 질병 조기 검출 장치 및 방법 |
| WO2025075256A1 (ko) * | 2023-10-06 | 2025-04-10 | (주)지놈포미 | 고심도 세포 유리 핵산 시퀀싱 기반의 질병 조기 검출 장치 및 방법 |
| CN117987556A (zh) * | 2024-02-23 | 2024-05-07 | 上海微荷医学检验实验室有限公司 | 用于确定肿瘤组织的目标CpG位点的甲基化水平的方法 |
| CN118448038A (zh) * | 2024-04-26 | 2024-08-06 | 天津大学 | 一种基于多组学动态ctDNA监测食管鳞状细胞癌疗效的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI813141B (zh) * | 2014-07-18 | 2023-08-21 | 香港中文大學 | Ｄｎａ混合物中之組織甲基化模式分析 |
| CN110168099B (zh) * | 2016-06-07 | 2024-06-07 | 加利福尼亚大学董事会 | 用于疾病和病症分析的无细胞dna甲基化模式 |
| CA3049457C (en) * | 2017-01-20 | 2023-05-16 | Sequenom, Inc. | Methods for non-invasive assessment of copy number alterations |
| BR112019018272A2 (pt) * | 2017-03-02 | 2020-07-28 | Youhealth Oncotech, Limited | marcadores metilação para diagnosticar hepatocelular carcinoma e câncer |
| CA3096678A1 (en) * | 2018-04-13 | 2019-10-17 | Grail, Inc. | Multi-assay prediction model for cancer detection |
| JP7455757B2 (ja) * | 2018-04-13 | 2024-03-26 | フリーノーム・ホールディングス・インコーポレイテッド | 生体試料の多検体アッセイのための機械学習実装 |
| CN112384982A (zh) * | 2018-06-06 | 2021-02-19 | 莱森特生物公司 | 用于指纹识别生物样本的方法 |
-
2020
- 2020-12-23 EP EP20907419.4A patent/EP4081665A4/en active Pending
- 2020-12-23 US US17/788,221 patent/US20230135171A1/en active Pending
- 2020-12-23 CA CA3165763A patent/CA3165763A1/en active Pending
- 2020-12-23 TW TW109145799A patent/TWI893039B/zh active
- 2020-12-23 WO PCT/US2020/066976 patent/WO2021133993A2/en not_active Ceased
- 2020-12-23 JP JP2022538934A patent/JP2023508947A/ja active Pending
- 2020-12-23 AU AU2020414737A patent/AU2020414737A1/en not_active Abandoned
- 2020-12-23 CN CN202080094820.5A patent/CN115087749A/zh active Pending
-
2025
- 2025-11-07 JP JP2025188196A patent/JP2026049725A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI893039B (zh) | 2025-08-11 |
| US20230135171A1 (en) | 2023-05-04 |
| WO2021133993A3 (en) | 2021-09-30 |
| EP4081665A2 (en) | 2022-11-02 |
| JP2023508947A (ja) | 2023-03-06 |
| CA3165763A1 (en) | 2021-07-01 |
| JP2026049725A (ja) | 2026-03-18 |
| EP4081665A4 (en) | 2024-01-10 |
| CN115087749A (zh) | 2022-09-20 |
| WO2021133993A2 (en) | 2021-07-01 |
| TW202138566A (zh) | 2021-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI893039B (zh) | 透過循環腫瘤dna分析之分子疾病評估之方法及系統 | |
| JP7851251B2 (ja) | 遺伝子サンプリングにおける統計的バイアスの軽減 | |
| US20240410016A1 (en) | Cd274 rearrangements as predictors of response to immune checkpoint inhibitor therapy | |
| US20240110230A1 (en) | Biomarkers for cancer treatment | |
| US20250019770A1 (en) | Circulating tumor dna fraction and uses thereof | |
| US20250201339A1 (en) | Use of combined cd274 copy number changes and tmb to predict response to immunotherapies | |
| WO2021096888A1 (en) | Methods of detecting a fusion gene encoding a neoantigen | |
| US20250003009A1 (en) | Fragment consensus methods for ultrasensitive detection of aberrant methylation | |
| JP2024519782A (ja) | がん治療のためのｃｄ２７４変異 | |
| US20250084482A1 (en) | Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer | |
| US20220392638A1 (en) | Precision enrichment of pathology specimens | |
| WO2025024258A2 (en) | Ebv status as a predictor of response to immunotherapy | |
| WO2025122504A1 (en) | Esr1 mutations, esr1 co-occurring mutations, and uses thereof | |
| WO2025122856A1 (en) | Use of fibroblast growth factor receptor 3 mutations and tumor mutational burden to predict response to immunotherapies | |
| EP4581170A2 (en) | Methods for evaluating clonal tumor mutational burden | |
| WO2025122500A1 (en) | Esr1 gene fusions and uses thereof | |
| WO2026030539A1 (en) | Alk mutations and uses thereof | |
| CN117794944A (zh) | 靶向肿瘤抗原的方法和材料 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |